Phase Ii Trial Of Neoadjuvant Chemoradiation With Concomitant Boost Followed By A Coycle Of Xelox In Locally Advanced Rectal Cancer

jin zhu,z zhang,wei gu,yajun xu,weiming shen,guoxiang cai,werner sun,sanjun cai

DOI: https://doi.org/10.1016/j.ijrobp.2011.06.569

2011-01-01

Abstract:IMRT with concomitant boost has showed efficacy in head and neck cancer but not proved in rectal cancer. Patients with pCR may have potential with lower recurrence and better overall survival. The prospective phase II trial was to evaluate the feasibility, toxicity, and response rate of preoperative concurrent chemoradiation with escalating dose by concomitant IMRT boost in locally advanced rectal cancer. Concurrent capecitabine plus oxaliplatin and one cycle of XELOX followed by CRT were used for the purpose of reduction of distance metastasis. Patients with T3-4 and/or N+ rectal cancer were treated at the Shanghai Cancer Hospital Fudan University, Shanghai from Sept 2008 to Nov 2010. All Patients received IMRT delivering 50 Gy (2 Gy/fraction) to the whole pelvis in concomitant with 55 Gy (2.2 Gy/fraction) to the primary tumor. Concurrent chemotherapy included oxaliplatin (50mg/m2 d1 weekly) and capecitabine (625mg/m2 bid, d1-5 weekly). One cycle of Xelox (oxaliplatin 130mg/m2 d1 + capecitabine 1000 mg/m2 bid d1-14) was given 2 weeks after the completion of concurrent chemoradiation, followed by radical surgery 8 weeks thereafter. Tumor response was evaluated by tumor regression grade (TRG) system and toxicity was evaluated by NCI-CTC 3.0 criteria. A total of 51 patients were accrued to this study. The median age was 57 (range, 37-71). Eighty-six percent patients had T3 disease and 77% had N+ disease. The median distance from the anal verge was 4.5 cm (range, 3-11cm). All patients completed chemoradiation per protocol. Seventeen patients underwent sphincter-sparing procedures. TRG was Grade 4 in 14 patients, Grade 3 in 25, Grade 2 in 8, and Grade 1 in 4 patients. The good response rate (TRG 3+4) was 76.5% (39/51) and the pCR rate was 27.4% (14/51). The grade 3 toxicities of hematologic, gastro-intestinal, and skin were 3.9%,17.6%, and 25.5%, respectively. No Grade 4 toxicity has been observed. Surgical complications (infection within 3 weeks of surgery) were observed in 5 patients; all were cured with intervention treatment. IMRT with concomitant boost is feasible in rectal cancer. Preoperative chemoradiation combined with capecitabine and oxaliplatin, followed by a cycle of Xelox is well tolerated and results in an encouraging pCR rate for patients with locally advanced rectal cancer. Longer follow up and large clinical trial will be further studied.